Introduction {#s1}
============

Common Neuropsychiatric Disorders (NPDs) are a major cause of morbidity and impairments in the quality of life around the world,^[@R1]^ with very large societal costs in the order of trillions of dollars.^[@R2]^ Several common NPDs (such as schizophrenia, bipolar disorder, Alzheimer's disease) have large heritabilities, with a possible shared pathophysiology for some of them, highlighting the importance of the study of genetic factors.^[@R3],[@R4]^ In recent years, dozens of genome-wide association studies (GWASs) have been carried out for NPDs.^[@R5]--[@R7]^ However, very few consistent and strong associations with NPDs have been found.^[@R3],[@R8]^

GWASs have been based in the common disease/common variant (CDCV) hypothesis. This hypothesis proposes that a single common variant could be a risk factor for a large fraction of patients.^[@R9]^ Several researchers have proposed that an alternative hypothesis, the common disease/rare variants (CDRV) could lead to the identification of additional risk factors for complex diseases, such as neuropsychiatric disorders.^[@R9]^ In the context of the CDRV hypothesis, a special interest is focused on functional variants, such as non- synonymous SNPs (nsSNPs), which are a minor fraction of the total number of SNPs. nsSNPs represent the most well understood group of genetic variants of possible functional importance.^[@R10]^ Alterations in dozens of genes involved in brain plasticity are responsible for increasing or decreasing the risk of NPDs.^[@R6]--[@R8],[@R11]--[@R13]^

In the present study, we screened *in silico* a large number of brain-expressed genes, identified 5 nsSNPs located in genes of neuropsychiatric relevance, developed novel genotyping assays and reported their frequencies in a sample of Colombian healthy subjects.

Methods {#s2}
=======

Bioinformatic analysis of candidate genes {#s2a}
-----------------------------------------

Several dozens of human brain-expressed genes were screened *in silico* for the presence of nsSNPs, using the BioMart tool.^[@R14]^ These genes correspond to several well-known functional categories, such as acetylcholine receptors, adaptor proteins, adhesion molecules, calcium channels, dopamine receptors, GABA receptors, glutamate receptors, potassium channels, protein kinases, protein phosphatases, serotonin receptors, signaling proteins, sodium channels, synaptic vesicle and transporters.MAF (\>0.01) in HapMap populations^[@R15]^ was screened to identify nsSNPs.

The catalog of GWAS from the National Human Genome Research Institute (<http://www.genome.gov/gwastudies>),^[@R5]^ the public database *BioGPS* (<http://biogps.org>),^[@R16]^ the Stanley Brain Database --SBD- (<https://www.stanleygenomics.org>)^[@R17]^ and the HuGeNavigator tool (<http://hugenavigator.net/>)^[@R18]^ were used for further functional annotation. The GWAS catalog contains information for available GWAS for diseases and phenotypes, BioGPS contains an extensive set of genome-wide expression data for a wide range of normal human tissues, SBD provides differential expression data for BP and SZ postmortem human brains and the HuGeNavigator contains data for existing meta-analysis of genes and diseases ([Tab. 1](#tbl_1){ref-type="table"}).

###### General information about brain-expressed candidate genes

  Gene Name                                                  Gene symbol   Position                         Size (bp)   Gene Expression in brain   Expression Changes   Meta-Analysis   GWAS
  ---------------------------------------------------------- ------------- -------------------------------- ----------- -------------------------- -------------------- --------------- -----------
  Clock circadian regulator                                  CLOCK         chr 4: 56,294,068-56,315,663     21,596      **PFC, PL, PN**            --                   --              PERS
  Neuronal PAS domain protein 2                              NPAS2         Chr 2: 101,436,614-101,613,291   176,679     **PFC, PL, PLB**           BP †, SZ †           --              CFJD, CFS
  Neuregulin 1                                               NRG1          Chr 8: 31,496,902-32,622,548     1,125,739   **PFC, PL, PLB**           --                   SZ              NAR
  Solute carrier family 18 (vesicular monoamine), member 1   SLC18A1       Chr 8: 20,002,366-20,040,717     38,352      **PFC, PL, STN**           --                   --              ALS, MD
  WW and C2 domain containing 1                              WWC1          Chr 5: 167,718,656-167,899,308   180,653     **HT, THAL, CN**           --                   EWM             MP

DNA sequences for flanking regions for the nsSNPs was obtained from the UCSC genome browser (<http://genome.ucsc.edu>).^[@R19]^ Primers were designed with the WASP^[@R20]^ (for allele- specific PCR, -AS-PCR-), Batch Primer3 and Primer1 online programs^[@R21],\ [@R22]^ (for Tetra Primer Allele-Specific PCR, -T-ARMS-PCR-). Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA, USA).

Genotyping of nsSNPs {#s2b}
--------------------

DNA samples, extracted from peripheral blood using a salting out method,^[@R23]^ from 171 unrelated Colombian subjects (122 women; mean age = 21.2; SD = 2.92) were genotyped for the 5 nsSNPs. None of the subjects had personal history of neuropsychiatric disorders. Written informed consent was obtained from all subjects and this study was approved by the institutional ethical committee^[@R24]^ and was conducted according to the Declaration of Helsinki Principles.

Conventional PCR (AS-PCR and T-ARMS-PCR) assays were carried out in Labnet MultiGene 96-well thermal cyclers (Labnet Internation al Inc, Edison, NJ, USA). Amplification reactions were performed in a total volume of 20 μl containing: 2 μl of genomic DNA (\~ 50 ng), 2.0 mM MgCl~2~, 10 X reaction Buffer, 1 mM of dNTPs, 1 M of Betaine and 0.8 U of Taq polymerase (Bioline, London, United Kingdom) (See [Table III](#tbl_3){ref-type="table"} for primers concentrations). PCR products were separated in a 2% agarose gel, stained with SYBR Safe (Invitrogen, Carlsbad, CA, USA) and visualized on a UV Transilluminator. Genotyping process for *NPAS2* gene was carried out in a CFX96 Touch Real-Time PCR system (BioRad, Hercules, CA, USA). To verify the consistency in the genetic results, a random subsample (10% of subjects) was re-genotyped for each nsSNP. In addition, two different investigators confirmed and validated the results, independently checking all genotypes.

NPAS2-rs2305160 was analyzed using a specific TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA). It was performed as follows: 2 μl (20 ng) genomic DNA, 1 X TaqMan^®^ Genotyping Master Mix (Applied Biosystems), 1 X of TaqMan Pre-Designed SNP Genotyping Assay (C\_\_15976652_10, Applied Biosystems) and water in a total volume of 10 μl. The amplification protocol consisted of 10-min denaturation step at 95°C (1 cycle), 95°C for 15s and 60°C for 90s (50 cycles).

Statistical analysis {#s2c}
--------------------

PLINK program was used for Hardy-Weinberg equilibrium analysis of genotype and allele frequencies.^[@R25]^ Allele frequencies for the five nsSNPs were compared using a 2 × 2 contingency table between Colombian subjects and HapMap samples: Utah Residents with Northern and Western European ancestry (CEU); Yoruba in Ibadan, Nigeria (YRI); Han Chinese in Bejing, China (CHB); Japanese in Tokyo, Japan (JPT); and Mexican ancestry from Los Angeles, USA (MXL). Results were considered statistically significant at *p*\<0.05

Results {#s3}
=======

An *in silico* screening of several dozens of human brain-expressed genes identified 5 nsSNPs (rs6855837; p.Leu395Ile, rs2305160; p.Thr394Ala, rs10503929; p.Met289Thr, rs2270641; p.Thr4Pro and rs3822659; p.Ser735Ala), with higher probabilities of being true positives (MAF\>0.01 in HapMap samples) ([Table 2](#tbl_2){ref-type="table"}). These nsSNPs are located in genes (CLOCK, NPAS2, NRG1, SLC18A1 and WWC1) with a high relevance for neuropsychiatric disorders and endophenotypes ([Table 1](#tbl_1){ref-type="table"}), supported by multiple lines of experimental evidence, such as genome-wide expression and association studies and meta-analysis of genetic association studies.

###### Details for novel nsSNPs in brain-expressed genes

  Gene          SNP          Location          Reference Allele   Minor Allele   Amino acid change   MAF-CEU   MAF-YRI   MAF-CHB   MAF-JPT   MAF-MEX
  ------------- ------------ ----------------- ------------------ -------------- ------------------- --------- --------- --------- --------- ---------
  **CLOCK**     rs6855837    chr4: 56319244    G                  T              p.Leu395Ile         0.004     0.326     0.006     0.006     0.040
  **NPAS2**     rs2305160    chr2: 101591304   C                  T              p.Thr394Ala         0.296     0.027     0.220     0.198     0.330
  **NRG1**      rs10503929   chr8: 32613983    T                  C              p.Met289Thr         0.173     0.000     0.000     0.000     0.120
  **SLC18A1**   rs2270641    chr8: 20038466    T                  G              p.Thr4Pro           0.376     0.106     0.256     0.333     0.286
  **WWC1**      rs3822659    chr5: 167858372   T                  G              p.Ser735Ala         0.035     0.350     0.207     0.186     0.070

We designed novel cost-effective genotyping assays, based in allele-specific PCR methods, for four of these nsSNPs ([Table 3](#tbl_3){ref-type="table"}). We genotyped these five nsSNPs in a sample of healthy subjects (CLB)**.** [Table 4](#tbl_4){ref-type="table"} shows the allele and genotype frequencies found in our samples. Minor allele frequencies for the five SNPs ranged between 4.1% (WWC1) and 24.3% (SCL18A1). All markers were in Hardy--Weinberg equilibrium (HWE) (p value \>0.05).

###### Primers and PCR conditions for genotyping assays, based in allele-specific PCR, for novel nsSNPs in brain-expressed genes

                Method            Allele bp   Primer sequence    Conc (μM)                                      Primer sequence   Conc (μM)                                                      
  ------------- ----------------- ----------- ------------------ ---------------------------------------------- ----------------- ---------------- --------------------------------------------- ------
  CLOCK         AS-PCR            T:122       Wildtype forward   5-TCA GCA GCT GTC TCA GGA GG-3                 1.0               Common reverse   5-TTT AAA CGA ATG ACC AGA CA-3                1.0
  p.Leu395Ile   53°C -35 cycles   G:122       Mutant forward     5-TCA GCA GCT GTC TCA GGA GT-3                 1.0                                                                              
  NRG1          T-ARMS-PCR        A:805 566   Forward 1          5-GCA GAG CCT TCG GTC TGA ACG AAA CA AGA C-3   1.0               Reverse 1        5-GTG AGG CCC ATT GGC AAT GTT CAG CA-3        1.0
  p.Met289Thr   63°C -35 cycles   G:805 269   Forward 2          5-CTC CCT TTC TTA TGT CCA GGA AAC AGC GG-3     0.2               Reverse 2        5-TCA AGG CGT CTG AAC AAA GGA GAG AGG CTC-3   0.2
  SLC18A1       T-ARMS-PCR        T:315 212   Forward 1          5-GCA ACC GCT GGG GAG CAT CCA GAA TAGG-3       1.0               Reverse 1        5-CAG TCC GGC CAT CAC CAT GCT CCA GA-3        1.0
  p.Thr4Pro     63°C -35 cycles   G:315 157   Forward 2          5-TCA AGC AGG GTG TAC ACT GCC TGC TGG G-3      0.4               Reverse 2        5-TTT CCT TCG TCT GGG CAG ACT CCC TCC C-3     0.4
  WWC1          T-ARMS-PCR        T:427 201   Forward 1          5-CAA TGA GGT GTT CTG GGT ATC CAC GT-3         0.75              Reverse 1        5-GTC TTC TGG TGA AGG GCT GGA TAA GC-3        0.75
  p.Ser735Ala   63°C -35 cycles   G:427 278   Forward 2          5-TGA TTC CCC AGA TTC CTC ACT TCT ACA AA-3     0.75              Reverse 2        5-CAG GGT AGA CCA ATC CCC ATA AAC ACA G-3     0.75

###### Allele and genotype frequencies for five novel nsSNPs

                *Clock* rs6855837   *NPAS2* rs2305160   *NRG1* rs10503929   *SLC18A1* rs2270641   *WWC1* rs3822659                                                                  
  ------------- ------------------- ------------------- ------------------- --------------------- ------------------ ----- ------- ------ ----- ------- ------ ----- ------- ------ -----
  GENOTYPE                          N                   \%                                        N                  \%            N      \%            N      \%            N      \%
  G/G           128                 74.9                C/C                 98                    57.3               T/T   142     83.0   T/T   100     58.5   T/T   157     91.8   
  G/T           41                  24.0                C/T                 66                    38.6               T/C   28      16.4   T/G   59      34.5   T/G   14      8.2    
  T/T           2                   1.1                 T/T                 7                     4.1                C/C   1       0.6    G/G   12      7.0    G/G   0       0.00   
                Total               171                 100                 Total                 171                100   Total   171    100   Total   171    100   Total   171    100
  ALLELE                            N                   \%                                        N                  \%            N      \%            N      \%            N      \%
  G             297                 86.8                C                   262                   76.6               T     312     91.2   T     259     75.7   T     328     95.9   
  T             45                  13.2                T                   80                    23.4               C     30      8.8    G     83      24.3   G     14      4.1    
                Total               342                 100                 Total                 342                100   Total   342    100   Total   342    100   Total   342    100
  HWE p value   0.81                0.60                0.96                0.73                  0.86                                                                              

We compared MAFs for these five nsSNPs found in the Colombian population with available data for samples from European, African, Asian and Latin American populations (extracted from HapMap). The YRI samples was the only population with significant differences for all genetic markers, with a *p* value less than 0.01 (see [Figure 1](#fig_1){ref-type="fig"}). For CHB and JPT samples, we observed significant differences for rs10503929 (*NRG1*) and rs3822659 (*WWC1*) SNPs (p\<0.002). Finally, the CLB samples showed allelic frequencies similar to those of MEX and CEU samples for all SNPs, with only one exception, rs6855837 SNP (MEX *p* = 0.039 and CEU *p*\<0.001).
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Discussion {#s4}
==========

Alterations in dozens of genes involved in brain and synaptic plasticity are responsible for a large number of common NPDs.^[@R11]--[@R13],[@R26]^ Genome-wide association studies, mainly focused on non-functional SNPs, have found a few consistent and strong associations with NPDs.^[@R3]^ nsSNPs represent the most well understood group of genetic variants of possible functional importance.^[@R10]^ Due to their impact on function of the encoded proteins, nsSNPs are not common in brain-expressed genes.^[@R10]^

We identified five nsSNPs in brain-expressed genes of high relevance for neuropsychiatric disorders: *CLOCK, NRG1, NPAS2*, *SLC18A1* and *WWC1*. *CLOCK* is a key regulator of the circadian system, and regulates the transcription of *PER1, PER2, PER3, CRY1* and*CRY2* genes. *NRG1* is known to mediate cell--cell interactions in the nervous system and has been implicated in the etiology of schizophrenia.^[@R27]^ *NPAS2* also has a key role the regulation of circadian mechanisms in the brain.^[@R28]^ *SLC18A1* encodes the vesicular amine transporter 1 (also known as VMAT1), important for the functioning of monoaminergic systems.^[@R29]^ WWC1 is involved in long-term potentiation mechanisms and synaptic plasticity.^[@R30]^ There is previous experimental evidence, arising from genome-wide expression and association studies, implicating the involvement of these genes in several neuropsychiatric disorders and endophenotypes, such as schizophrenia, mood disorders or memory performance.^[@R27]--[@R30]^ However, a large part of the previously studied variants in these genes were neutral polymorphisms.^[@R5]^ Similary the SNP detection method has wide applications and can be used for diagnosis of other untreated neurodegenerative disorders such as ALS, Parkinson's and AMD as shown.^[@R31]--[@R37]^

Cost-effective genotyping assays described in this work for these nsSNPs could be interesting methodological alternatives for researchers in developing and developed countries. These five nsSNPs in brain-expressed genes represent interesting candidates to analyze in future genetic studies of neuropsychiatric disorders and related endophenotypes, a focused synaptogenomics approach.^[@R12],[@R13],[@R26]^
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